Attached files
file | filename |
---|---|
8-K - CURRENT REPORT - Sanara MedTech Inc. | smti_8k.htm |
Exhibit 99.1
Sanara
MedTech Inc. Announces the Appointment of Bob DeSutter to Its Board
of Directors
FORT WORTH, TX / ACCESSWIRE / October 15, 2020 / Sanara MedTech
Inc. Based in Fort Worth, Texas, Sanara MedTech Inc.
("Sanara" or the "Company") (OTCQB:SMTI), a provider of wound and
skin care products and virtual consult services dedicated to
improving patient outcomes, announced today that Bob DeSutter has
been appointed to the Company's Board of Directors (the "Board"),
effective October 12, 2020.
Ron
Nixon, Sanara's Executive Chairman stated, "Bob is a great addition
to our Board. He has a wealth of knowledge and experience in the
medtech segment of the healthcare industry, and we believe that he
will provide great judgement, insights, and disruptive thinking as
we continue to execute on our long-term comprehensive wound and
skin care strategy."
Bob
DeSutter is a managing director in Piper Sandler healthcare
investment banking. He has 27 years of healthcare investment
banking experience at Piper Sandler and served as global group head
from 2003 to 2018. Over that period, the group became one of the
leading and most respected healthcare investment banking
practices.
"I have
been following Sanara's product cadence and growth for many years
and am honored to join the Board and assist the Company in
executing its strategy in the advanced wound and skin care
markets," said DeSutter.
About Sanara MedTech Inc.
With a
focus on improving patient outcomes through evidence-based healing
solutions, Sanara MedTech Inc. markets and distributes wound and
skin care products and services to physicians, hospitals, clinics,
and all post-acute care settings. We are constantly seeking
long-term strategic partnerships with a focus on products that
produce efficacious outcomes at a lower overall cost. Our products
are primarily sold in the North American advanced wound care and
surgical tissue repair markets. Sanara MedTech markets and
distributes CellerateRX® Surgical
Activated Collagen® to the surgical
markets as well as the following products to the wound care market:
BIAKŌS™ Antimicrobial Skin and Wound Cleanser,
HYCOL™ Hydrolyzed Collagen, and PULSAR II™ Advanced
Wound Irrigation™ (AWI). In addition, Sanara is actively
seeking to expand within its six focus areas of wound and skin care
for the acute, post-acute, and surgical markets. The focus areas
are debridement, biofilm removal, hydrolyzed collagen, advanced
biologics, negative pressure wound therapy adjunct products, and
the oxygen delivery system segment of the healthcare industry. For
more information, visit SanaraMedTech.com.
Information about Forward-Looking Statements
The
statements in this press release that do not constitute historical
facts are "forward-looking statements," within the meaning of and
subject to the safe harbor created by the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by terms such as "may," "will," "would," "should," "expect,"
"plan," "anticipate," "could," "intend," "target," "project,"
"contemplates," "believes," "estimates," "predicts," "potential" or
"continue" or the negatives of these terms, variations of these
terms or other similar expressions. These forward-looking
statements include statements regarding the development of new
products and expansion of the Company's business in telehealth and
wound care. These items involve risks, contingencies and
uncertainties such as product demand, market and customer
acceptance, the effect of economic conditions, competition,
pricing, the ability to consummate and integrate acquisitions, and
other risks, contingencies and uncertainties detailed in the
Company's SEC filings, which could cause the Company's actual
operating results, performance or business plans or prospects to
differ materially from those expressed in, or implied by these
statements. All forward-looking statements speak only as of the
date on which they are made, and the Company undertakes no
obligation to revise any of these statements to reflect the future
circumstances or the occurrence of unanticipated events, except as
required by applicable securities laws.
Investor Contact:
Callon
Nichols
Director
of Investor Relations
713-826-0524
CNichols@sanaramedtech.com
SOURCE: Sanara MedTech Inc.